Genflow Biosciences (LSE:GENF) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


What is Genflow Biosciences Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Genflow Biosciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LSE:GENF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Genflow Biosciences's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genflow Biosciences Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genflow Biosciences's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Genflow Biosciences's Margin of Safety % (DCF Earnings Based) falls into.


Genflow Biosciences Business Description

Other Exchanges GENFF:USAWQ5:Germany
Address 6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.